674 related articles for article (PubMed ID: 18091190)
1. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
[TBL] [Abstract][Full Text] [Related]
2. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
3. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
[TBL] [Abstract][Full Text] [Related]
4. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness.
Lasser RA; Bossie CA; Zhu Y; Locklear JC; Kane JM
Ann Clin Psychiatry; 2007; 19(2):65-71. PubMed ID: 17612845
[TBL] [Abstract][Full Text] [Related]
5. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
6. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W
J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
[TBL] [Abstract][Full Text] [Related]
7. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
Lasser RA; Bossie CA; Zhu Y; Gharabawi G; Eerdekens M; Davidson M
Int J Geriatr Psychiatry; 2004 Sep; 19(9):898-905. PubMed ID: 15352149
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients.
Kissling W; Glue P; Medori R; Simpson S
Hum Psychopharmacol; 2007 Dec; 22(8):505-13. PubMed ID: 17902187
[TBL] [Abstract][Full Text] [Related]
10. Long-acting risperidone in stable patients with schizoaffective disorder.
Mohl A; Westlye K; Opjordsmoen S; Lex A; Schreiner A; Benoit M; Bräunig P; Medori R
J Psychopharmacol; 2005 Sep; 19(5 Suppl):22-31. PubMed ID: 16144783
[TBL] [Abstract][Full Text] [Related]
11. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
[TBL] [Abstract][Full Text] [Related]
12. Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial.
Byerly MJ; Nakonezny PA; Rush AJ
Psychiatry Res; 2008 May; 159(1-2):115-20. PubMed ID: 18295343
[TBL] [Abstract][Full Text] [Related]
13. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder.
Lasser R; Bossie CA; Gharabawi G; Eerdekens M; Nasrallah HA
J Affect Disord; 2004 Dec; 83(2-3):263-75. PubMed ID: 15555724
[TBL] [Abstract][Full Text] [Related]
15. Long-acting risperidone improves negative symptoms in stable psychotic patients.
Curtis VA; Katsafouros K; Möller HJ; Medori R; Sacchetti E
J Psychopharmacol; 2008 May; 22(3):254-61. PubMed ID: 18308804
[TBL] [Abstract][Full Text] [Related]
16. Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia.
Macfadden W; Bossie CA; Turkoz I; Haskins JT
Int Clin Psychopharmacol; 2010 Mar; 25(2):75-82. PubMed ID: 20101185
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
Li H; Rui Q; Ning X; Xu H; Gu N
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
[TBL] [Abstract][Full Text] [Related]
18. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720
[TBL] [Abstract][Full Text] [Related]
19. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.
Hawley C; Turner M; Latif MA; Curtis V; Saleem PT; Wilton K
Hum Psychopharmacol; 2010 Jan; 25(1):37-46. PubMed ID: 20041474
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.
Chue P; Eerdekens M; Augustyns I; Lachaux B; Molcan P; Eriksson L; Pretorius H; David AS
Eur Neuropsychopharmacol; 2005 Jan; 15(1):111-7. PubMed ID: 15572280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
